Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and ...

Soft earnings didn't appear to concern Bio-Techne Corporation's ( NASDAQ:TECH ) shareholders over the last week. We ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...

Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...

Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results this Wednesday before market open. Here’s ...

Bio-Techne’s primary source of funding for acquisition activity is a $600 million revolving credit facility, established in August 2018. This credit facility can be extended to an additional $200 ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

Shares of Bio-Techne Corp. TECH slid 4.09% to $65.86 Thursday, on what proved to be an all-around grim trading session for ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of ...